|
|
| Small Stocks, Big Money™ |
| Weekly Newsletter |
|
|
|
|
|
|
|
NOAA Certifies TMC’s Massive USA B Seafloor Exploration License, Advancing Access to 1 Billion-Tonne Critical Metals Resource
The Metals Company (Nasdaq: TMC) announced that NOAA has formally certified its USA B exploration license application, marking a key regulatory milestone for a seafloor area containing an estimated 1.02 billion tonnes of polymetallic nodules rich in nickel, cobalt, copper, manganese, and rare earth elements. The certification initiates NOAA’s Environmental Impact Statement process and represents another step forward in unlocking one of the world’s largest undeveloped critical minerals resources for U.S. energy, defense, manufacturing, and infrastructure supply chains.
|
|
|
|
Gorilla Technology Delivers 55% Revenue Growth, Achieves Positive Operating Cash Flow and Raises 2026 Outlook
Gorilla Technology (Nasdaq: GRRR) reported a strong start to 2026 with first-quarter revenue climbing 55% year-over-year to $28.2 million, while operating cash flow turned positive at $6.6 million, marking a $17.3 million improvement from the prior year period. Backed by a 373% increase in cash reserves to $98.4 million and growing momentum across its AI infrastructure and data center initiatives, the company raised its full-year 2026 revenue guidance to $160-$200 million and highlighted a potential annualized AI infrastructure opportunity exceeding $500 million.
|
|
|
|
|
Virax Reports Promising Long COVID Test Data, Targets Multi-Million Patient Diagnostic Market
Virax Biolabs (Nasdaq: VRAX) announced encouraging early clinical results for ViraxImmune™, its blood-based immune profiling test being developed for Long COVID, ME/CFS and related post-acute infection syndromes. In pilot data, the test achieved 88% specificity and 92% positive predictive value, supporting advancement into larger validation studies as the company targets a potential U.S. market of up to 21 million adults living with Long COVID and related conditions, with approximately 2.5 million new cases emerging annually.
|
|
|
|
|
|
|
Calidi Showcases RedTail Cancer Platform at ASCO, Advances Lead Programs Toward Clinical Development
Calidi Biotherapeutics (NYSE American: CLDI) announced the acceptance of two abstracts at the 2026 ASCO Annual Meeting highlighting its proprietary RedTail systemic virotherapy platform and lead candidates CLD-401 and CLD-501. Preclinical data demonstrated the platform’s ability to selectively target tumors and deliver potent genetic medicines directly into the tumor microenvironment, with CLD-401 expected to enter the clinic following a planned IND filing by year-end 2026 and CLD-501 expanding the platform’s potential in solid tumors through its novel in situ T-cell engager approach.
|
|
|
|
|
Enlivex’s RAIN Treasury Surpasses $1.1 Billion as Rain Protocol Accelerates Growth in Prediction Markets
Enlivex (Nasdaq: ENLV) reported that its treasury now holds approximately 79.6 billion RAIN tokens valued at $1.16 billion, underscoring the company's expanding exposure to the rapidly growing prediction markets sector. The update comes as the Rain Foundation strengthens its leadership team with five high-profile advisory board appointments and announces a $100 million liquidity commitment, helping position Rain as the world's third-largest prediction market protocol by total value locked and reinforcing Enlivex's long-term conviction in the ecosystem.
|
|
|
Recent News
|
RedChip TV
|
|
|
|
RedChip Highlights Foremost Clean Energy Ltd. (NASDAQ: FMST) & BioVie (NASDAQ: BIVI)
|
|
|
|
|
|
|
|
|
|
For decades, scientists have known that oncolytic viruses — viruses engineered to seek out and destroy cancer cells — are among the most potent anti-tumor agents ever discovered. The concept is elegant: inject a virus that replicates exclusively inside cancer cells, kills them, and then triggers the immune system to mop up what's left. In the lab, results have been spectacular.
Off The Hook YS Inc. (NYSE-A: OTH) is a vertically integrated, AI-powered marine marketplace focused on buying, selling, and financing pre-owned boats across the United States. Its core platform, anchored by WeBuyBoats.com and a growing national broker network, operates as a liquidity engine in the fragmented $10 billion used boat market, a segment where the majority of transactions still happen without the speed, transparency, or data infrastructure that modern commerce demands.
First Phosphate Corp. (OTCQX-ADR: FPHOY | OTCQX: FRSPF | CSE: PHOS) is a Quebec-based critical minerals developer building a vertically integrated supply chain for lithium iron phosphate (LFP) battery materials in North America. The company's flagship Bégin-Lamarche Property in the Saguenay–Lac-Saint-Jean region of Quebec is a rare, large-scale igneous phosphate deposit being advanced toward a full feasibility study. On January 7, 2026, Mark Reichman, Managing Director of Equity Research at Noble Capital Markets, maintained an Outperform rating and a price target of US$1.55 per share on First Phosphate Corp., representing implied upside of approximately 104% from the share price of $0.76.
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company using artificial intelligence to discover and develop precision oncology therapies. Its lead asset, LP-300, is currently in a Phase 2 clinical trial targeting never-smoker non-small cell lung cancer (NSCLC), a patient population with no FDA-approved therapy specifically designed for them. On March 31, 2026, Lake Street Capital Markets reaffirmed a Buy rating and $25 price target on Lantern Pharma (NASDAQ: LTRN), implying upside of more than 1,400% from current levels. The near-term catalyst is a Type C meeting with the FDA scheduled for May 14, 2026.
OBOOK Holdings, Inc. (Nasdaq: OWLS) is rapidly positioning OwlPay as a next-generation cross-border payments backbone, leveraging stablecoin rails to deliver near-instant settlement at dramatically lower costs—addressing a global market projected to reach $320 trillion by 2032. With expanding regulatory licenses, major partnerships like Visa Direct, and projected revenue growth accelerating toward $100M+, the company is converting its compliance moat into high-margin, recurring infrastructure revenue.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases and advanced liver disease. Its lead asset, bezisterim (NE3107), is an orally available small molecule targeting neuroinflammation and insulin resistance, which are two of the principal biological drivers behind Parkinson's disease (PD), Alzheimer's disease (AD), and Long COVID. The company received a buy rating and $6 price target from Brookline Capital Markets in March 2025.
|
|
Future Tech Investor Conference: Profiting from Technologies Transforming Work, Life, and Industry
Profiting from Technologies Transforming Work, Life, and Industry, delivers direct access to publicly traded innovators across artificial intelligence, automation, digital infrastructure, advanced manufacturing, and next-generation enterprise solutions.
|
| Unlock Smarter Investing with RedChat |
 |
| Tired of sifting through endless filings? Let RedChat do the heavy lifting. Get real-time, data-driven insights on over 2,000 small-cap stocks—instantly. Save time, make informed decisions, and stay ahead of the market. |
| Access RedChat now, free of charge. |
|
|
|
|
Recent Research Coverage Updates

| Company |
Rating |
Price Target |
Firm |
Report Date |
| First Phosphate (OTCQX: FRSPF) | Buy | $1.65 | Noble Capital | April 14, 2026 |
| Gorilla Technology (Nasdaq: GRRR) | Buy | $39 | AGP | March 3, 2026 |
| The Metals Company (Nasdaq: TMC) | Buy | $11 | Wedbush | February 22, 2026 |
| The Metals Company (Nasdaq: TMC) | Buy | $9 | Cantor Fitzgerald | February 22, 2026 |
| Alliance Entertainment (Nasdaq: AENT) | Buy | $9 | Noble Capital | February 13, 2026 |
| Alliance Entertainment (Nasdaq: AENT) | Buy | $8 | Maxim | February 13, 2026 |
| XTI Aerospace (Nasdaq: XTIA) | Buy | $3 | Maxim | February 6, 2026 |
| New Horizon Aircraft (Nasdaq: HOVR) | Buy | $18 | Jones Trading | February 2, 2026 |
| Sixty Degrees Pharmaceuticals (Nasdaq: SXTP) | Buy | $24 | HC Wainwright | February 2, 2026 |
| New Horizon Aircraft (Nasdaq: HOVR) | Buy | $18 | Jones Trading | February 2, 2026 |
| Lantern Pharma (Nasdaq: LTRN) | Buy | $28 | Rodman & Renshaw | February 1, 2026 |
| Off The Hook (NYSE American: OTH) | Buy | $10 | ThinkEquity | January 19, 2026 |
| Enlivex Therapeutics (Nasdaq: ENLV) | Buy | $13 | HC Wainwright | January 13, 2026 |
| NioCorp Developments (Nasdaq: NB) | Buy | $8.7 | Freedom Capital Markets | January 7, 2026 |
|

|
|
|
 |
| Small Stocks, Big Money™ Podcast |
| The podcast features in-depth interviews with CEO's from the top names in small-cap stocks, providing listeners with a unique perspective not found anywhere else. |
| Available on: |
|
|
|
|
|
|
Upcoming Events
|
|
|
BioVie (NASDAQ: BIVI)
4:15pm Eastern
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson’s disease and long COVID) and advanced liver disease.
|
|
|
|
Foremost Clean Energy (NASDAQ: FMST)
4:15pm Eastern
Foremost Clean Energy Ltd. (NASDAQ: FMST) (CSE: FAT) (WKN: A3DCC8) is a rapidly growing North American uranium and lithium exploration company.
|
|
|
|
Calidi Biotherapeutics (NYSE American: CLDI)
4:15pm Eastern
Calidi Biotherapeutics is a clinical-stage biotechnology company advancing the next generation of targeted immunotherapies through its innovative systemic delivery platform, RedTail.
|
|
|
|
Archived Events
|
|
|
Clinch Resources (TSX: CLCH)
4:15pm Eastern
Clinch Resources, Ltd. is a Tennessee-based metallurgical mining company with its corporate office located in Knoxville, Tennessee and operations in West Virginia.
|
|
|
|
Virax Biolabs Group (NASDAQ: VRAX)
4:15pm Eastern
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases.
|
|
|
|
Quote of the Week
|
“ If you're happy to sit at your desk and not take any risk, you'll be sitting at your desk for the next 20 years. ” |
|
|
|
|
Order “Small Stocks, Big Money™” Today!
Dave Gentry's new book, Small Stocks, Big Money: Interviews With Microcap Superstars, is now available for pre-order. Published by Wiley Finance, this first-hand perspective and insider information on the fast world of microcap investing is now available for purchase.
|
|
|
|
|
|
|
Lesson of the Week
Read about the key principle's of Charles Diker's investment philosphy.
|
|
|
|
|
|
You are receiving this email because you have subscribed to receive updates from us. Should you wish to cancel your subscription, please click here to manage preferences.
|
|
|
|
|